Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible

(2010) Martin Köbel et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Constitutional Methylation of the BRCA1 Promoter Is Specifically Associated with BRCA1 Mutation-Associated Pathology in Early-Onset Breast Cancer

(2010) E. M. Wong et al.   Cancer Prevention Research

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval

(2010) Peter C. Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression

(2010) Michael H Roh et al.   MODERN PATHOLOGY

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

(2008) Joshua Z Press et al.   BMC CANCER

Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma

(2008) C. Blake Gilks et al.   HUMAN PATHOLOGY

Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type and BRCA1 loss

(2008) Blaise Clarke et al.   MODERN PATHOLOGY